Proactive Investors - Run By Investors For Investors

Breakfast Alert - VI mining, SimplyBiz, Life Settlement and more...

Breakfast Alert - VI mining, SimplyBiz, Life Settlement and more...

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

954*

Total number of AIM Companies trading:

905*

*as at close of business  21 February 2018

 

Standard List**  of Main Market:

 Total number of Standard List Companies

 (Incl Susp): 

136*

Total number of Standard List Companies trading:

123*

*as at close of business  21 February 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

86*

Total number of NEX Growth Market Companies trading:

82*               

*as at close of business 21 February 2018

 

                                *A corporate client of Hybridan LLP

 

**  Standard Listing as defined by Hybridan LLP to be a business with strictly  operational activity

                             

Dish of the day

No Joiners Today 

Off the menu   

No Leavers Today

        

What’s cooking in the IPO kitchen?

NEX Exchange

VI mining—is an emerging gold and silver producer, focused on developing gold tolling operations in for small scale miners in Peru. Offer TBC. Due around 28 Feb.

AIM

SimplyBiz, a Financial Services Firm, reported to be considering an IPO targeting a market capitalisation of between £140m and £155m in a listing that would raise £30m of new money.

Bacanora Lithium—Readmission. No new money. Mkt cap £140m. Due 21 March. the new holding company for Bacanora Minerals Ltd 

Stirling Industries—Acquisition vehicle focusing on industrials. Offer TBA. Due 5 March.

GRC International Group— holding company for a group of companies providing a range of products and services to address the IT governance, risk management and compliance requirements of organisations. Offer TBC, expected 5 Mar 2018

Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area. Vendor placing and new funds to a total of €225m, Target gross proceeds €207m. Expected 21 Feb

Polarean  - Medical drug-device combination company operating in the high resolution medical imaging market. Offer TBC. Due Early March

Block Energy—a  NEX Listed UK based oil exploration and production company whose main country of operation is the Republic of Georgia, looks to join AIM end of February 2018. Offer TBC

 

Main Market Specialist Funds

Life Settlement—closed-ended investment company whose principal activities will be to support and manage portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the US.  Due 6 Mar.

 

Main Market Premium Listing

Augmentum Fintech—Seeking to raise £100m at £1. Focused strategy to invest in fast growing and/or high potential private fintech companies in the UK and wider Europe

Energean Oil & Gas—Seeking gross proceeds of c.$500m. Independent oil and gas exploration and production company focused on  exploration, development and production of assets in the Eastern Mediterranean . Due march 2018.

IntegraFin provides platform services to UK clients and their financial advisers through its award-winning platform, Transact. Due Mar 18. FYSep2017 PBT up 44% to £29.9m.

JTC Group Jersey based financial services firm reported to be considering London float with c. £300m valuation.

 

Breakfast buffet

Sareum Holdings* (LON:SAR) 0.95p £26.1m

“The specialist cancer drug discovery and development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, announced yesterday that it will present preclinical data demonstrating that its Chk1 inhibitor, SRA737, synergizes with niraparib, a poly ADP-ribose (PARP) inhibitor, in a poster at the American Association of Cancer Research (AACR) Annual Meeting 2018 being held in Chicago, USA from 14-18 April. PARP inhibitors prevent the repair of DNA damage and are developed as treatments for cancer and other indications. Niraparib is an orally active small molecule PARP inhibitor approved in the US to treat ovarian cancer.  Sierra Oncology holds exclusive and worldwide rights for the Chk1 inhibitor, SRA737, having licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund in September 2016.”

 

Milestone Group* (LON:MSG) 0.19p £3.53m

Final results from the provider of digital media and technology.

Deborah White replaced by Anthony Sanders as CEO (on an interim basis)

Edward Guy Meyer appointed as Business Development Director

Review of operations led to cessation of charitable and social activities

Strategy revised to focus on blockchain-based services to the digital media and fintech markets

OnGuard contract renewals and extensions agreed

Post period end: Software license agreement entered into with Envoy Group Corp Inc

MoU signed to create a joint venture with Seed Media Ltd and Martin Heath

Settlement Agreement with respect of failed placing (October 2016) dispute

“Protecting the interest of the Company's shareholders is a priority and the Board's strategy is to seek to raise funds on a basis that is fair to all.” Rev £29k. Net loss £2.3m.

 

Albert Tech (LON:ALB) 30p £18.7m

“Albert Technologies is pleased to announce it has reached agreement with one of the top 5 global advertising agencies for a pilot project. The onboarding process is currently under way, and indicates Albert's steady progress in marketing the power of its AI platform to drive transformative performance and value in digital marketing.

During the past few months, Albert has been gaining traction with large global media agencies interested in deploying its autonomous digital marketing technology. Coupling Albert's AI technology with the global reach of such agencies and the enormous resources they currently deploy to execute their customers' marketing strategies, provides an exciting market development opportunity for all parties.”

 

APC Technology  (APC.L) 8p £10.79m

AGM statement.

“At its Annual General Meeting that takes place later today, APC Technology Group PLC, the provider of design-in, specification and distribution services for specialist electronic components and systems, lighting technologies and connectivity products, will make the following statement concerning current trading:

"The Board are pleased with the start to the new fiscal year and can confirm that the Company continues to trade comfortably within management expectations."

The results for the half-year ending 28 Feb 2018 are expected to be announced in April 2018.”

 

Xpediator (XPD.L) 38.5p £45.2m

The “provider of freight management services across the UK and Europe, is pleased to announce a trading update for the year ended 31 Dec 2017. Group revenues for FY 2017 will be up by approximately 59% to £116m (2016: £72.8m) reflecting approximately £10m of revenue contribution from the three acquisitions completed during 2017, and positive performances from all three of the Group's trading divisions. Trading profit is also expected to be significantly ahead of the previous year despite investment in strengthening the Company's key operating functions to support the current and future growth of the business. The Group trading results for FY 2017 are expected to be in line with market expectations. Xpediator intends to announce its final results for FY 2017 in May 2018.”  FYDec18E rev £134.97m, PBT £6.2m.

 

Shield Therapeutics (STX.L) 24.5p £33.18m

Business and trading update.

Revenues for the year ended 31 Dec 2017 expected to be £637,000 (2016: £304,000), in line with Board expectations.

Year-end unaudited cash position was £13.3m (2016: £21.0m)C

Cost rationalisation programme being implemented -Current cash runway extended to at least the end of Q4 2018

Full review of Shield's strategic options underway 

Feraccru remains commercially available through Shield Therapeutics and it European partners, with more patients than ever being treated

Detailed analysis of the AEGIS-CKD pivotal Phase III full dataset underway

 

easyHotel (LON:EZH) 114.5p £115.07m

“The owner, developer, operator and franchisor of super budget branded hotels, today announces a conditional placing of 45,454,546 new ordinary shares of 1p each in the capital of the Company at a price of 110p per Placing Share to raise approximately £50m. The Placing Shares represent approximately 45.2% of the Ordinary Shares in issue as at the date hereof and the Placing Price represents a discount of approximately 3.9% to the closing mid-market price of 114.5p per Existing Ordinary Share on 21 Feb 2018, being the latest practicable date prior to the publication of this  Announcement.”   Proceeds to be primarily utilised to fund the acceleration of the Group's owned hotel roll-out strategy.

 

Erris Resources (LON:ERIS) 23p £7.15m

“The European focused mineral exploration company with a portfolio of zinc prospects in Ireland and gold projects in Sweden, is pleased to provide an update on its operations in Ireland. At the 100% owned Abbeytown project in County Sligo, Erris Resources has completed in-fill soil geochemistry surveys and started drilling at the Skreen prospect. Drilling at Skreen is part of a programme to test high priority zinc targets in the Abbeytown district.

Additionally, Erris Resources has applied for eighteen new contiguous prospecting licences in an area east of Galway”.

 

Ingenta  (ING.L) 123.5p £20.9m

The “provider of software and services to the global publishing industry, is pleased to announce that Sainsbury's has today signed a 3-year contract for our Ingenta Advertising solution.

The SaaS-based solution will become operational in the first half of 2018, and will enable Sainsbury's staff and international brands to manage  digital advertising space, through an online portal.

 

Ingenta Advertising has processed over £1bn in advertising revenues since inception and is used by major information providers around the world.”FYDec17E rev £16.35m and PBT of £0.6m. 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use